Kane Biotech (CVE:KNE) Hits New 1-Year Low – Time to Sell?

Shares of Kane Biotech Inc. (CVE:KNE) reached a new 52-week low during trading on Thursday . The stock traded as low as C$0.09 and last traded at C$0.09, with a volume of 11500 shares changing hands. The stock had previously closed at C$0.10.

Kane Biotech Stock Down 10.0 %

The stock has a market capitalization of C$12.97 million, a price-to-earnings ratio of 2.25 and a beta of 0.52. The company has a debt-to-equity ratio of -331.42, a current ratio of 0.80 and a quick ratio of 0.39. The business has a fifty day moving average of C$0.10 and a 200 day moving average of C$0.11.

Insider Buying and Selling at Kane Biotech

In related news, Director Marc Edwards bought 2,000,000 shares of the stock in a transaction on Friday, January 17th. The stock was bought at an average price of C$0.10 per share, with a total value of C$200,000.00. Company insiders own 37.21% of the company’s stock.

About Kane Biotech

Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections.